---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-087506"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2026-08-11T12:05:36+00:00"
generated_at: "2026-08-11T12:10:36.523821+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara Q2 net loss $21.7M; guides ADVANCED-2 enrollment completion, THRIVE-3 interim results to 4Q 2026

## Summary
- Q2 2026 net loss of $21.7M ($0.36/share) vs. $15.0M ($0.35/share) in Q2 2025.
- Cash and equivalents of $161.9M at June 30, 2026; expected to fund operations into 2028.
- ADVANCED-2 BCG-Unresponsive cohort enrollment completion expected 4Q 2026; ADVANCED-3 redesigned as exploratory trial.
- STARBORN-1 showed 83% (10/12) clinical success, 100% (10/10) evaluable; BLA for TARA-002 in LMs expected 2H 2027.
- R&D expenses rose to $17.0M from $10.8M YoY; THRIVE-3 interim results expected in 4Q 2026.

## SEC filing metadata
- accession: 0001213900-26-087506
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2026-08-11T12:05:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/0001213900-26-087506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea0299236-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-087506
- JSON: https://secwatch.observer/filing/0001213900-26-087506.json
- Plain text: https://secwatch.observer/filing/0001213900-26-087506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.